Figure 3 from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma

<p><b>A</b>, Median number of total expanded T-cell clones by response across the durvalumab plus bevacizumab, durvalumab monotherapy, T75 + D, STRIDE, and tremelimumab monotherapy arms, and all of the tremelimumab-containing arms combined. <b>B</b>, Proportion of participants with >32 expanded T-cell clones in the durvalumab plus bevacizumab, durvalumab monotherapy, T75 + D, STRIDE, and tremelimumab monotherapy arms. For panel <b>A</b>, <i>P</i> values were derived from a Wilcoxon test comparing response arms. Statistical analysis included nonevaluable participants (zero value total expanded T-cell clones). The lower and upper hinges of each boxplot are at the first and third quartiles. Boxplot whiskers extend to the most extreme value no further than 1.5 × IQR. Horizontal bar in each boxplot is at the median value. For panel <b>B</b>, the proportion of responders who either had more or less than or equal to the durvalumab median of 32 clones is shown. Analysis data cutoff: November 06, 2020. D, durvalumab monotherapy; NA, not available; T, tremelimumab monotherapy.</p>